Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysosomal membrane permeabilization (LMP) is a cellular event in which the integrity of the lysosomal membrane is compromised, allowing the release of lysosomal contents—primarily hydrolytic enzymes such as cathepsins—into the cytosol. This process can trigger various forms of cell death, including apoptosis and necrosis, and plays a significant role in both physiological regulation and disease pathology. LMP can be induced by reactive oxygen species (ROS), lysosomotropic agents, endogenous proteins like Bax, and cellular stressors. Regulatory factors include lipid composition of lysosomal membranes, p53, Bcl-2 family proteins, and the TORC1 signaling pathway. Dysregulation or increased susceptibility to LMP has been implicated in cancer cells' resistance/sensitivity to therapy.
Inducing destabilization/permeabilization for selective killing of diseased cells, Stabilizing/maintaining lysosomal integrity where excessive permeability contributes to pathology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysosomal Membrane Permeabilization Pathway (None).